Kaleido Biosciences, Inc. (KLDO)

Kaleido Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Net Income	-90.29	-81.62	-86.33	-61.74	-27.56
Depreciation & Amortization	2.36	1.82	1.32	0.79	0.32
Other Amortization	0.71	0.7	0.04	-	-
Loss (Gain) From Sale of Assets	-0.13	0.17	-	0	-
Stock-Based Compensation	10.34	12.68	10.07	6.96	0.59
Other Operating Activities	0.18	0.18	0.33	1.18	0.15
Change in Accounts Payable	0.28	3.3	-0.68	1.84	0.01
Change in Other Net Operating Assets	-0.54	1.25	-0.53	4.66	4
Operating Cash Flow	-77.09	-61.52	-75.8	-46.32	-22.5
Capital Expenditures	-1.13	-4.02	-3.59	-3	-1.41
Sale of Property, Plant & Equipment	0.44	-	-	-	-
Investing Cash Flow	-0.69	-4.02	-3.59	-3	-1.41
Long-Term Debt Issued	-	-	37.5	-	9.96
Long-Term Debt Repaid	-	-0.07	-30.09	-0.11	-0.09
Net Debt Issued (Repaid)	-	-0.07	7.41	-0.11	9.88
Issuance of Common Stock	70.4	40.55	68.39	0.12	3.02
Repurchase of Common Stock	-0.34	-	-	-	-
Other Financing Activities	-0.02	-0.08	-1.16	-2.08	-0.06
Financing Cash Flow	70.04	40.4	74.64	98.91	49.74
Net Cash Flow	-7.75	-25.14	-4.74	49.59	25.84
Free Cash Flow	-78.22	-65.54	-79.38	-49.32	-23.9
Free Cash Flow Margin	-7085.42%	-6722.26%	-	-	-
Free Cash Flow Per Share	-1.87	-1.96	-3.09	-9.65	-5.35
Cash Interest Paid	2.13	1.93	0.88	0.94	0.34
Levered Free Cash Flow	-46.02	-36.73	-49.72	-26.4	-13.59
Unlevered Free Cash Flow	-44.96	-35.68	-49.14	-25.77	-13.31
Change in Net Working Capital	1.83	-3.26	2.78	-7.4	-4.08

Updated Apr 1, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.